Patients' characteristics at baseline per treatment arm in the high-risk and low-risk group
| High risk | Low risk | ||||
|---|---|---|---|---|---|
| COBRA Classic | COBRA Slim (high risk) | COBRA Avant Garde | MTX-TSU | COBRA Slim (low risk) | |
| Number of patients | 98 | 98 | 93 | 47 | 43 |
| Age (years) | 53.2±11.9 | 51.8±13.1 | 51.1±12.8 | 51.0±14.0 | 51.4±14.4 |
| BMI (kg/m2) | 26.0±4.3 | 26.8±4.2 | 26.5±4.2 | 27.0±4.2 | 25.4±4.3 |
| Gender (female) | 65.3% | 64.3% | 68.8% | 80.9% | 76.7% |
| Smoking status (ever) | 57.1% | 59.2% | 60.2% | 38.3% | 48.2% |
| Alcohol intake | 55.1% | 56.1% | 54.8% | 61.7% | 55.8% |
| Symptom duration (weeks) | 33.8±35.5 | 33.2±38.2 | 44.3±65.9 | 33.1±62.2 | 34.4±68.2 |
| Disease duration (weeks) | 1.8±3.1 | 2.6±3.3 | 3.1±6.4 | 3.2±6.6 | 1.9±2.7 |
| Employed before symptom onset | 52.0% | 65.3% | 62.4% | 66.0% | 55.8% |
| Employed at screening | 44.9% | 53.1% | 51.6% | 57.4% | 51.2% |
| Comorbidities at screening | 72.4% | 74.5% | 65.6% | 66.0% | 60.5% |
| RF positivity | 79.6% | 83.7% | 75.3% | 23.4% | 25.6% |
| ACPA positivity | 77.6% | 79.6% | 77.4% | 23.4% | 27.9% |
| Erosions present | 32.7% | 32.7% | 34.4% | 0.0% | 2.3% |
| Total TJC | 14.7±9.5 | 13.7±8.2 | 14.1±9.0 | 14.1±8.6 | 13.1±10.7 |
| Total SJC | 11.9±8.9 | 10.8±6.5 | 10.6±6.7 | 10.0±7.0 | 10.9±7.6 |
| PGA (0–100) | 59.5±21.7 | 56.2±21.7 | 54.8±24.2 | 49.9±23.0 | 48.6±30.7 |
| Pain (0–100) | 59.5±23.6 | 56.5±21.9 | 57.5±23.8 | 52.1±23.2 | 48.2±31.2 |
| Fatigue (0–100) | 50.6±26.0 | 49.0±21.3 | 48.9±23.7 | 45.9±22.1 | 39.4±27.7 |
| PhGA (0–100) | 54.7±18.5 | 53.1±18.1 | 51.7±17.9 | 48.3±23.4 | 48.6±20.8 |
| ESR (mm/h) | 33.5±25.2 | 32.1±23.4 | 25.0±17.6 | 23.0±16.9 | 30.0±29.4 |
| CRP (mg/l) | 19.7±28.9 | 21.5±33.2 | 14.5±19.2 | 13.5±18.6 | 20.1±39.3 |
| DAS28(ESR) | 5.4±1.3 | 5.2±1.2 | 5.0±1.3 | 4.8±1.7 | 4.9±1.6 |
| DAS28(CRP) | 5.0.±1.2 | 4.8±1.1 | 4.7±1.2 | 4.6±1.6 | 4.5±1.6 |
| HAQ (0–3) | 1.2±0.7 | 1.0±0.7 | 1.0±0.6 | 1.0±0.7 | 0.9±0.9 |
Values reported are proportions or mean±SD.
ACPA, anticitrullinated protein antibody; alcohol intake, consumption of any form of alcohol; BMI, body mass index; CRP, C-reactive protein; DAS28, 28 joint disease activity score; disease duration, time elapsed between diagnosis of RA and start of treatment; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; MTX, methotrexate; PGA, patient global assessment; PhGA, physician global assessment; RF, rheumatoid factor; SJC, swollen joint count; symptom duration, time elapsed between onset of symptoms and start of treatment; TJC, tender joint count; TSU, tight step-up.